Afuresertib - Novartis Oncology

Drug Profile

Afuresertib - Novartis Oncology

Alternative Names: 2110183; Afuresertib hydrochloride; ASB-183; GSK-2110183; GSK2110183B; GSK2110183C

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Novartis Oncology; University Health Network
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules; Thiophenes
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Gastric cancer; Haematological malignancies; Histiocytosis; Multiple myeloma; Ovarian cancer; Solid tumours

Most Recent Events

  • 31 Jul 2018 Afuresertib licensed to Laekna Therapeutics worldwide
  • 20 Jun 2018 GlaxoSmithKline completes a phase II trial for Cancer and Haematological malignancies in USA, Australia, Canada, Ireland and South Korea (NCT01531894)
  • 30 Jun 2017 University Health Network, Toronto and Novartis completes a phase II trial in Chronic lymphocytic leukaemia (combination therapy, Second-line therapy or greater) in Canada (PO) (NCT01532700)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top